Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Blood (2024) 144 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2024-202392

Published: 2024

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Blood (2022) 140 (Supplement 1): 4426–4427.

https://doi.org/10.1182/blood-2022-164572

Published: 2022

Journal Articles

The Impact of BMI on the Outcome of Lymphoma Treatment

Najib Dally, Jackie Saleem, Khalil Tarabeh, Marat Kashlikov

Blood (2022) 140 (Supplement 1): 12042.

https://doi.org/10.1182/blood-2022-165973

Published: 2022

Journal Articles

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu, Galia Rahav, Shai Levi, Andrei Braester, Gilad Itchaki, Osnat Bairey, Najib Dally, Lev Shvidel, Tomer Ziv-Baran, Aaron Polliack, Tamar Tadmor, Ohad Benjamini, on behalf of the Israeli CLL Study Group

Blood (2022) 139 (5): 678–685.

https://doi.org/10.1182/blood.2021014085

Published: 2022

Includes: Supplemental data

Journal Articles

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Rosa Ruchlemer, Uri Abadi, Lev Shvidel, Andrei Braester, Raanan Cohen, Neta Frankel, Keren Ofek, Jenia Berelovich, Moshe Grunspan, Ohad Benjamini

Blood (2021) 138 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2021-146504

Published: 2021

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Noam Benyamini, MD, Adir S, MD, Moshe E. Gatt, MD, Yael C Cohen, MD, Irit Avivi, MD, Svetlana Trestman, MD, Olga Shvetz, MD, Tamar Tadmor, MD, Najib Dally, MD, Yevgeny Chober, Hila Magen, MD, Chezi Ganzel, MD, Osnat Jarchowcky Dolberg, Celia Suriu, MD, Noa Lavi, MD

Blood (2018) 132 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2018-99-115985

Published: 2018

Journal Articles

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Tamar Tadmor, MD, Andrei Braester, MD, Najib Dally, MD, Ariel Aviv, Yair Herishanu, MD, Mona Yuklea, MD, Lev Shvidel, MD, Naomi Rahimi-Levene, MD, Rosa Ruchlemer, MD, Ariela Arad, MD, Claudia Fogl, MD, Aaron Polliack, MD, Lee Magal, PhD, Kelly Townsend, PhD

Blood (2018) 132 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2018-99-113771

Published: 2018

Journal Articles

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Merav Barzilai, MD, Ilya Kirgner, MD, Martin Ellis, MD, Irit Avivi, MD, Najib Dally, MD, Uri Rozovski, Noa Lavi, MD

Blood (2017) 130 (Supplement 1): 2917.

https://doi.org/10.1182/blood.V130.Suppl_1.2917.2917

Published: 2017

Journal Articles

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Noa Lavi, MD, Maya Koren-Michowitz, MD, Avi Leader, MD, Adi Shacham-Abulafia, MD, Shirley Shapira, MD, Najib Dally, MD, Evgeni Chubar, MD, Elena Mishchenko, MD, Martin H. Ellis, MD

Blood (2015) 126 (23): 4081.

https://doi.org/10.1182/blood.V126.23.4081.4081

Published: 2015

Journal Articles

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Martin H. Ellis, MD, Noa Lavi, MD, Elena Mishchenko, MD, Najib Dally, MD, David Lavie, MD, Anna Courevitch, MD, Odit Gutwein, MD, Shlomo Bulvik, MD, Andrei Braester, MD, Evgeni Chubar, MD, Sigal Tavor, MD, Adrian Duek, MD, Ilya Kirgner, MD, Maya Koren-Michowitz, MD

Blood (2014) 124 (21): 1830.

https://doi.org/10.1182/blood.V124.21.1830.1830

Published: 2014

Journal Articles

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Drorit Merkel, MD, Kalman Filanovsky, MD, Ariel Aviv, MD, Moshe E. Gatt, MD, Yair Herishanu, MD, Ariela Arad, MD, Tamar Tadmor, MD, Najib Dally, MD, Aharon Ronson, MD, Luiza Akria, MD, Andrei Braester, MD, Arnon Nagler, MD, Ronit Leiba, MSc., Yishai Ofran, MD

Blood (2011) 118 (21): 3811.

https://doi.org/10.1182/blood.V118.21.3811.3811

Published: 2011

Journal Articles

Massive Transfusion in Wartime: Experience from Northern Israel, Summer 2006.

Eldad J. Dann, MD, Najib Dally, MD, Judith Chezar, PhD, Moshe Michaelson, MD, Mirit Barzelay, Andrei Braester, MD, Ron Hoffman, MD, Lilach Bonstein, PhD

Blood (2007) 110 (11): 4017.

https://doi.org/10.1182/blood.V110.11.4017.4017

Published: 2007

NARROW

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

The Impact of BMI on the Outcome of Lymphoma Treatment

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Massive Transfusion in Wartime: Experience from Northern Israel, Summer 2006.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only